Selank: A GABAergic Anxiolytic Analog with a Thin Western Evidence Base

The short version

Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, an endogenous tetrapeptide fragment of immunoglobulin G that the body uses to modulate immune and stress responses. The C-terminal Pro-Gly-Pro tail was added, as with Semax, to slow enzymatic breakdown. In rodent and limited human research, Selank reduces anxiety — not by sedating the system like benzodiazepines, but by acting as a positive allosteric modulator of GABA receptor binding ^[8] and by shifting the expression of GABA-pathway genes in frontal cortex ^[10].

The honest framing: most efficacy data are from rodents or small Russian clinical studies. There are no FDA- or EMA-approved indications, no large Western randomized controlled trials, and the human evidence is limited to short trial courses in Russian patients with anxiety disorders. Selank is not a regulated pharmaceutical in the United States; it is a research chemical. This page reports what the published studies show; it is not medical advice and carries no human dosing.

What it is

Selank (also called TP-7) is a synthetic heptapeptide anxiolytic derived by extending the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with the metabolic-stabilizing Pro-Gly-Pro tripeptide at its C-terminus. Tuftsin itself is a fragment of the Fc region of IgG heavy chains and naturally engages immune and phagocytic regulation — Selank inherits some of that immune-signaling character while gaining the CNS anxiolytic and nootropic properties studied in its own right.

Outside Russia, Selank has no approved pharmaceutical form. It is supplied as a research chemical, typically as a lyophilized powder reconstituted for intranasal or subcutaneous use in laboratory settings.

How it works

The primary anxiolytic mechanism is positive allosteric modulation of GABA receptor binding. In rat brain membrane preparations, Selank modulates [³H]GABA binding in a subtype-selective, concentration-dependent manner that differs from benzodiazepines — it can even block the modulatory activity of diazepam and olanzapine at distinct binding sites ^[8]. At the gene-expression level, Selank administration changed the expression of 45 GABA-pathway genes in rat frontal cortex one hour after dosing and 22 genes at three hours, with the pattern positively correlated to that induced by GABA itself ^[10].

A second convergent mechanism is enkephalin-degrading enzyme inhibition. In human serum in vitro, Selank inhibited neprilysin-type enkephalinases at an IC50 of approximately 20 micromolar ^[7] — about half the potency of Semax — which is proposed to extend endogenous enkephalin signaling and contribute to the anxiolytic and mood-stabilizing effects.

At the neurotrophin level, intranasal Selank increased BDNF expression in the rat hippocampus ^[11], suggesting a neuroplasticity-linked mechanism that may underlie the reported cognitive dimension of its effects. In human patients with anxiety-asthenic disorders, Selank shifted Th1/Th2 cytokine balance and modulated peripheral-blood IL-6 expression ^[12] — characterizing it as an immunomodulator as well as an anxiolytic, which reflects its tuftsin lineage.

The combination of GABAergic, opioid-peptide, neurotrophic and immune-signaling activity across multiple systems is mechanistically plausible but also means interactions with medications targeting any of those systems are unstudied.

What the research shows

GABAergic mechanism and allosteric modulation. A 2018 review established that Selank's anxiolytic activity centers on positive allosteric modulation of GABA receptor binding with subtype-selective, concentration-dependent effects different from benzodiazepines ^[8]. This remains the best-characterized molecular finding.

Anxiety reduction in UCMS. In rats subjected to unpredictable chronic mild stress, combining diazepam with Selank produced the largest anxiety reduction of any treatment arm tested — a co-administration effect consistent with their shared GABAergic action and supporting the allosteric-modulation model ^[9].

GABAergic gene expression. In rat frontal cortex, Selank produced a significant, time-dependent change in 45 GABA-pathway genes at one hour and 22 at three hours, with expression shifts that positively correlated to those induced by GABA itself ^[10].

BDNF upregulation in hippocampus. Intranasal Selank increased BDNF expression in the rat hippocampus in vivo, linking the peptide to neuroplasticity pathways and providing a candidate mechanism for the reported nootropic dimension beyond anxiety relief ^[11].

Human immunomodulation in anxiety patients. In a clinical study with patients diagnosed with anxiety-asthenic disorders, Selank shifted Th1/Th2 cytokine balance and modulated IL-6 expression — the most direct human molecular data in the corpus, confirming the immunomodulatory profile inherited from tuftsin ^[12].

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence). The nootropic community's most consistent report is a calm without sedation — the volume on background anxiety turned down while energy and clarity hold steady, explicitly contrasted with the heavy, foggy quality of benzodiazepines. Situational use before high-stakes events (exams, presentations, difficult conversations) is very commonly described, with users reporting fewer nerves and a heart rate that stayed low. A "calm but sharp" focus quality — attributed to quieted anxious mental chatter rather than a direct stimulant push — is frequently mentioned. A substantial minority report little or no perceptible effect; this is an honest and common outcome. Adverse effects from the same communities include mild nasal irritation from the intranasal solution, occasional headache, and, in a minority, slightly too much calm or mental softness that some users tie to heavier use.

Cited safety cautions. Several cautions emerge from the literature:

• Unregulated research-chemical supply. Outside Russia, Selank is not a pharmaceutical product; identity, purity and actual peptide content vary by supplier and are not independently guaranteed.
• Long-term safety not established. Human data are confined to short Russian trial courses in diagnosed patients; there is no long-term independent safety follow-up.
• Multi-system interaction unknowns. Selank touches GABAergic, opioid-peptide, monoaminergic and immune-signaling systems ^{[8][9][10][12]}. Combination with GABAergic sedatives, opioids, or serotonergic/dopaminergic drugs carries unstudied additive-effect risk.
• Immune-signaling activity. As a tuftsin analog, Selank shifts Th1/Th2 balance and cytokine levels ^[12]. Long-term consequences for people with autoimmune conditions, active infection, or immune-modulating medications are not characterized.
• Not a substitute for clinical anxiety care. Persistent or impairing anxiety is a medical condition with evidence-based treatments and clinical oversight. An unapproved research peptide is not a substitute for professional evaluation.

Where it fits

Among the three peptides on this desk, Selank approaches the cognitive-nootropic question through the anxiety axis — its mechanism is the most directly human-relevant of the three (with a clinical immunomodulation finding in actual patients ^[12]) and it has the clearest separation from a sedative risk profile. Against Semax, which operates primarily through BDNF/NGF and neuroprotection, Selank is the anxiolytic complement — quiet focus through anxiety relief rather than growth-factor upregulation. Against DSIP, it offers a more characterized mechanism. See the comparison page for a structured view across all three.